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Predictors of Epstein-Barr virus serostatus and 
implications for vaccine policy: A systematic 
review of the literature
Background Epstein-Barr virus (EBV) is an important human pathogen; it in-
fects >90% people globally and is linked to infectious mononucleosis and sev-
eral types of cancer. Vaccines against EBV are in development. In this study 
we present the first systematic review of the literature on risk factors for EBV 
infection, and discuss how they differ between settings, in order to improve 
our understanding of EBV epidemiology and aid the design of effective vacci-
nation strategies.
Methods MEDLINE, Embase, and Web of Science were searched on 6th March 
2017 for observational studies of risk factors for EBV infection. Studies were 
excluded if they were published before 2008 to ensure relevance to the modern 
day, given the importance of influencing future vaccination policies. There were 
no language restrictions. After title, abstract and full text screening, followed by 
checking the reference lists of included studies to identify further studies, data 
were extracted into standardised spreadsheets and quality assessed. A narrative 
synthesis was undertaken.
Results Seventy-seven papers met our inclusion criteria, including data from 31 
countries. There was consistent evidence that EBV seroprevalence was associat-
ed with age, increasing throughout childhood and adolescence and remaining 
constant thereafter. EBV was generally acquired at younger ages in Asia than 
Europe/North America. There was also compelling evidence for an association 
between cytomegalovirus infection and EBV. Additional factors associated with 
EBV seroprevalence, albeit with less consistent evidence, included ethnicity, so-
cioeconomic status, other chronic viral infections, and genetic variants of HLA 
and immune response genes.
Conclusions Our study is the first systematic review to draw together the global 
literature on the risk factors for EBV infection and includes an evaluation of the 
quality of the published evidence. Across the literature, the factors examined 
are diverse. In Asia, early vaccination of infants would be required to prevent 
EBV infection. In contrast, in Western countries a vaccine could be deployed 
later, particularly if it has only a short duration of protection and the intention 
was to protect against infectious mononucleosis. There is a lack of high-qual-
ity data on the prevalence and age of EBV infection outside of Europe, North 
America and South-East Asia, which are essential for informing effective vacci-
nation policies in these settings.
Electronic supplementary material: 
The online version of this article contains supplementary material.
journal of
health
global
© 2020 The Author(s)
JoGH © 2020 ISGH
Epstein-Barr Virus (EBV) is a herpesvirus that infects 90%-95% of humans, causing 
lifelong infection [1,2]. EBV infection during childhood is generally asymptomatic, 
however acquisition of EBV during adolescence or early adulthood often causes in-
fectious mononucleosis (IM) [3]. EBV is associated with 1% of global cancers, par-
ticularly Hodgkin’s lymphoma, Burkitt’s lymphoma, nasopharyngeal cancer (NPC) 
and gastric cancer [4].
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EBV infection is not currently treatable or preventable by vaccination, although the National Institutes of 
Health have stated that an EBV vaccine is an important goal [5]. Vaccines are currently in development 
which could protect against EBV infection or EBV-associated disease [6]. It is critical for vaccine develop-
ment to know the target product profile for a potential vaccine, which is only possible with a good un-
derstanding of the underlying epidemiology of infection and disease.
The epidemiology of EBV infection is not well understood. Seroprevalence increases with age, and sero-
positivity appears to occur at younger ages in resource-limited countries [7,8]. Whilst 90%-95% of people 
are infected by age 25, a small proportion (5%-10%) remain seronegative throughout their life [9]. EBV 
infection is correlated with human cytomegalovirus (CMV) infection [10,11], another herpesvirus which 
infects a high proportion of the population from a young age and is linked to reduced life expectancy [12]. 
Unlike CMV, the impact of EBV seronegativity on the life course is unknown. Our immune systems and 
EBV are likely well-adapted to each other, given the co-evolution of humans and virus [13,14]. Beyond 
this, studies of EBV epidemiology are sparse, and there has been no attempt to synthesise the global liter-
ature on the factors associated with EBV serostatus. Such syntheses are critical, as a greater understand-
ing of EBV epidemiology, including the dynamics of EBV infection in different sub-populations and the 
long-term health impacts of remaining EBV-seronegative, will be necessary for the vaccine development.
Given the importance of systematically collating, describing and formal critical evaluations of the evidence, 
we conducted the first systematic epidemiological literature review of risk factors for EBV infection, and 
discuss the implications of our findings for future EBV vaccination policy.
METHODS
Search strategy and study selection
MEDLINE, Embase, and Web of Science were searched on 6th March 2017 for articles on risk factors for 
EBV infection. The search terms included variations of ‘human herpesvirus 4’, ‘Epstein-Barr virus’, ‘in-
fectious mononucleosis’, ‘glandular fever’, ‘serostatus’, ‘risk factor’, ‘cross-sectional study’, ‘cohort study’, 
‘case-control study’, ‘clinical trial’ and ‘human’; the full search terms are shown in Supplementary item 1. 
Studies published before 2008 were excluded to ensure that the risk factors reported are relevant in the 
present day. Title, abstract and full-text screening was split between HRS and CJ, with 10% overlap. Dis-
agreements were resolved by consensus. Studies were included if they contained data on the percentage 
of people with antibodies against EBV stratified by age or any other risk factor. Studies were excluded if 
they examined risk factors for EBV-associated disease (eg, IM, cancers or autoimmune conditions) rath-
er than infection, if there was no comparison group, or if they did not include original research (reviews, 
editorial pieces, case reports).
Data extraction, synthesis and quality assessment
Data extraction and quality assessment was split between HRS and JRW, with 10% overlap to ensure con-
sistency. Data were extracted into a pre-designed spreadsheet that recorded the study design, study pop-
ulation, and EBV seroprevalence, stratified by risk factor. Discrepancies between reviewers were resolved 
by consensus. Studies published in languages other than English were extracted by an additional review-
er, with additional quality control by JRW. Where studies reported data on risk factors for multiple EBV 
antigens, we report data only for the most commonly reported antigen (EBV viral capsid antigen, VCA), 
but state where other data were available. As there was substantial heterogeneity in study design, reporting 
and the risk factors examined, we present a narrative synthesis of our findings in place of a meta-analysis.
The quality of included studies was assessed using a checklist adapted from Downs and Black [15], as 
per the guidance issued by Deeks et al [16]. Sufficient adjustment for confounding was defined as ad-
justing for age, sex, ethnicity or country of birth, and some measure of socioeconomic status; this was a 
pragmatic decision based on common confounders and prior knowledge. For the purposes of the sam-
ple size calculation, age was treated as the main exposure of interest. As per Downs and Black, when as-
sessing the power of studies, we calculated the minimum sample size per strata that would be required 
to detect a change in EBV seroprevalence from 95% to 85%, with power ranging from 70%-99%. Con-
servatively, we assumed only two strata and a ratio of 1:1 between exposure strata. Different thresholds 
were used for case-control studies and for cohort or cross-sectional studies. These criteria were scored 
from 0 (<70% power) to 5 (>99% power).
This review was registered on PROSPERO (CRD42017059811).
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RESULTS
Search results and included studies
Our literature search yielded 22 074 results after de-duplication. After exclusion of papers published be-
fore 2008 (n = 11 600), and title, abstract and full-text screening (Figure 1), 77 studies were included 
(Table S1 in the Online Supplementary Document). Three otherwise eligible studies were excluded; 
one as all participants were seropositive for EBV, one as only one patient was seronegative and one study 
which was a meta-analysis of the association between latitude and EBV seroprevalence which defined lat-
itude based on the study location rather than participant-level data. Studies ranged in size from 8-61 273 
participants, EBV seroprevalence ranged from 6%-91%. The global distribution of studies is shown in 
Figure 2. There were 12 case-control studies (3 nested within cohorts), 13 cohort/longitudinal and 16 
which reported only cross-sectional results but were part of cohort. Thirty-three were cross-sectional, and 
the design of two other retrospective studies was unclear.
Study populations included population-level studies of healthy individuals (n = 42), pregnant women 
(n = 3) and healthy family members of people with NPC (n = 3), and studies of specific patient popula-
Figure 1. PRISMA flowchart of studies included in the systematic review.
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tions such as transplant recipients (n = 7), those infected with the human immunodeficiency virus (HIV, 
n = 5), and others (including haemophilia and heart disease, n = 17).
Quality assessment of included studies
The results of our quality assessment are presented in Table S2 in the Online Supplementary Document. 
Thirty-eight studies examined EBV serostatus as their primary outcome and 39 as a secondary outcome. 
Only ten adequately adjusted for confounding, however there were no discernible differences between 
the results of these studies and the other studies included. Many studies lacked power; the impact of this 
is discussed throughout. Misclassification of serostatus may also have occurred as many studies used in-
house, unvalidated assays for detecting EBV antibodies (Table S1 in the Online Supplementary Docu-
ment); these studies tended to be smaller and were less likely to satisfy other quality criteria.
Age and EBV seroprevalence
Fifty-eight studies examined age as a risk factor for EBV serostatus; the majority (n = 32) found EBV se-
roprevalence increased with age (Table 1) [8,17-43,45-48]. There was a clear trend towards increasing 
EBV seroprevalence with age up to the age of 24 years (Figure 3), particularly when studies with <100 
participants (n = 5) were excluded. Studies in older individuals (≥25 years) showed little change in sero-
prevalence.
When stratifying by age and study location and restricting the analysis to studies with populations rep-
resentative of the general underlying population (n = 13 for participants <25 years), the data showed 
EBV infection occurred earlier in people in Asia than people in Europe and North America (Figure 3). 
In Asia EBV seroprevalence rapidly increased with age, exceeding 80% by age 5, and 90% by 7-8 years 
[19,21,36,47]. In contrast, studies in Europe and North America showed a more gradual increase in se-
roprevalence which did not exceed 90% until age 22 [23,25,28,33,38,43,49,53,79,83]. Studies which 
used validated, commercially available tests for EBV antigens were more likely to show increases in se-
roprevalence with age than studies which used in-house tests or did not reported which test they used; 
these studies also tended to be larger and representative of the underlying population (Table S1 in the 
Online Supplementary Document). Only thirteen studies fulfilled our power criteria across all age cat-
egories (Table S2 in the Online Supplementary Document); the remainder of the literature was consis-
tent with the findings of these studies.
Most (12/16) studies that reported no association with age were of adult populations [10,53-63], suggest-
ing that age only influences EBV seroprevalence during childhood.
Figure 2. The global distribution of study populations included in the literature review. The size of the blue dots is 
proportional to the total number of individuals included in studies from each country. The number inside the dot 
refers to the number of studies with participants in each country.
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Table 1. Summary of sociodemographic and lifestyle factors associated with EBV serostatus in the literature*
Risk factoR foR EBV sERostatus summaRy of REsults
Age Seronegativity decreased with age: 28 studies [8,17-44]
Seronegativity decreased with age after 6 months: 3 studies [45-47]
Seronegativity decreased with age after 18 months: 1 study [48]
No association (children included): 4 studies [49-52]
No association (all/vast majority adults): 12 studies [10,53-63]
Sex/gender Women were more likely to be seronegative: 8 studies [22,49,57,59,62,64-66]
Men were more likely to be seronegative: 6 studies [18,30,32,34,50,51]
No association in children, but adult women were less likely to be seronegative: 1 study [26]
Differences by sex interacted with marital status: 1 study [67]
No association: 20 studies [8,17,19,20,23,29,42-44,54-56,60,61,63,68-72]
Ethnicity Seroprevalence was lower for white participants than those of other ethnicities: 3 studies [20,43,71]
EBV seronegativity was higher in people of Han ethnicity than other Chinese ethnicities: 1 study [57]
No association: 7 studies [31,34,53,69,73-75]
Year of participation in study No association: 2 studies [28,76]
Country of study No difference between Japan and Jamaica: 1 study [77]
Higher EBV seroprevalence in Mexico than Papua New Guinea, Columbia, Italy, Netherlands and Israel: 1 study [78]
Place of birth EBV seronegativity was higher in central/Eastern China than Western China: 1 study [57]
EBV seronegativity was higher among people of European/North American origin than other world regions: 2 studies [10,79]
No association: 5 studies [19,20,36,37,55]
Socioeconomic status (SES) EBV seronegativity was associated with higher SES: 1 study [10]
No association between EBV and SES: 1 study [73]
No association with occupational/social class: 3 studies [57,60,69]
Higher household income was associated with EBV seronegativity: 2 studies [43,71]
No association with household income: 1 study [20]
EBV seronegativity was associated with having medical insurance for non-white participants: 1 study [43]
No association with having private medical insurance: 1 study [75]
Level of education Seronegativity increased with higher levels of education: 5 studies [10,19,20,43,57]
No association with level of education of study participant: 2 studies [34,75]
EBV seronegativity was higher among those whose parents had been in education for longer: 2 studies [10,71]
No association with parental education: 1 study [8]
Anthroposophic lifestyle No association: 1 study [24]
Urban/rural setting EBV seronegativity lower in urban areas than rural areas: 1 study [10]
No association: 1 study [21]
Household size/structure Number of siblings
EBV seroprevalence increased with number of siblings: 3 studies [10,66,71]
No association between number of siblings and EBV seropositivity: 2 studies [8,55]
Birth order
No association with birth order: 2 studies [25,55]
Number of people in household
Adults with more children in the house were more likely to be EBV seropositive: 1 study [69]
No association between number of adults in the house and EBV serostatus: 1 study [69]
EBV seroprevalence increased with household size: 1 study [79]
No association with household size: 1 study [53]
Crowding of home No association: 4 studies [20,25,43,69]
Housing type (flat/house) No association: 1 study [66]
Marital status EBV seronegativity higher in unmarried women than married women, but lower in unmarried men than married men: 
1 study [67]
No association: 3 studies [19,53,57]
Sexual behaviour EBV seroconversion was associated with deep kissing: 1 study [55]
Smoking status Smoking
Smoking associated with EBV seropositivity: 3 studies [10,39,79]
Increased association with greater exposure: 1 study [39]
No association: 6 studies [19,56,60,61,64,75]
Passive smoking
Mother smoking associated with lower EBV seronegativity: 1 study [66]
No association: 1 study [25]
Weight/body mass index 
(BMI)
Increased BMI was associated with lower rates of seroprevalence: 4 studies [64,79-81]
No association: 2 studies [71,75]
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Risk factoR foR EBV sERostatus summaRy of REsults
Diet General dietary factors
No association with diet: 1 study [55]
No association with eating sufficient food: 1 study [82]
No association with eating balanced meals: 1 study [82]
No association with a reliance on low-cost food: 1 study [82]
Specific foods
No association with salted fish consumption: 3 studies [39,56,61]
No association with frequency of fruit and vegetable consumption: 2 studies [56,82]
No association with frequency of eating leafy salad: 1 study [82]
No association with frequency of eating wholegrain bread: 1 study [82]
No association with frequency of eating beans: 1 study [82]
No association with frequency of eating red meat: 1 study [82]
No association with betel nut consumption: 1 study [56]
No association with slow-cooked soup consumption: 1 study [39]
No association with preserved vegetable consumption: 1 study [39]
Specific drinks
No association with frequency of drinking milk: 1 study [82]
No association with frequency of drinking juice: 1 study [82]
No association with tea consumption: 1 study [39]
No association with herbal tea consumption: 2 study [39]
Alcohol consumption No association: 3 studies [19,39,56]
Formaldehyde/solvent  
exposure
No association: 1 study [56]
Exercise No association: 1 study [55]
Height No association: 2 studies [60,64]
Birth factors (baby) Vaginal vs caesarean delivery
No association: 3 studies [25,66,71]
Premature birth
No association: 3 studies [25,66,71]
Birth weight
No association: 3 studies [8,66,71]
Maternal characteristics Maternal parity
No association: 1 study [53]
Maternal age
No association: 2 studies [8,71]
Maternal smoking/alcohol use during pregnancy
No association: 1 study [71]
Maternal BMI prior to pregnancy
No association: 1 study [71]
Maternal fever during third trimester
No association: 1 study [71]
Stress No association with stress: 1 study [55]
No association with parental stress: 1 study [25]
Attended daycare Attendance
Attending daycare was associated with higher EBV seropositivity: 1 study [66]
No association: 2 studies [20,71]
Age of starting daycare
Daycare attendance at a younger age was associated with greater EBV seropositivity: 1 study [25]
No association: 1 study [66]
Hygiene practices No association with frequency of house cleaning: 1 study [25]
No association with frequency of handwashing: 1 study [25]
No association with having pets in the house: 2 studies [25,66]
Swimming No association with attending a swimming pool: 1 study [25]
Duration of watching  
television
No association with daily duration of watching television: 1 study [25]
BMI – body mass index, SES – socio-economic status, EBV – Epstein-Barr virus
*Adjusted results are presented where they were available, otherwise unadjusted associations are reported. There was some overlap in the data used by 
five studies based on data from the US National Health and Nutrition Examination Surveys [43,76,79,82,83]. To avoid over-representing the findings 
from this population, for each risk factor we have only included the findings of the largest study in this table.
Table 1. Continued
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Figure 3. EBV seroprevalence by age in studies identified from the literature. Panel A. In participants up to 24 years 
of age. Panel B. In participants over 24 years of age. Panel C. In participants up to 24 years of age in Europe and 
North America. Panel D. In participants up to 24 years of age in Asia. Panel E. In participants up to 24 years of 
age in studies representative of their underlying populations in Europe and North America, (f) in participants up 
to 24 years of age in studies representative of their underlying populations in Europe and North America. Sero-
prevalence data categorised by age group was extracted from the literature and data points were plotted at the mid-
point of each age group. Studies with only one data point above or below 24 years were excluded from the relevant 
graph. Studies were considered generalisable to the underlying population if it was a random sample of healthy in-
dividuals and the study population was representative of the local population.
Other sociodemographic factors and EBV seroprevalence
The majority of studies (19/36) reported no association between sex and EBV serostatus (Ta-
ble 1) [8,17,19,20,23,29,42,43,54-56,60,61,63,68-72]. Studies which reported associations 
[18,22,26,30,32,34,49-51,57,59,62,64-67] were evenly split in their findings, with no discernible dif-
ferences according to study type, population or location, although they were generally small and lacking 
in power; 9/15 had ≤75 participants.
Relatively few studies (n = 11) compared EBV seroprevalence between participants of different ethnicities 
or countries of birth. The majority found no association [31,34,53,69,73-75], but three reported sero-
prevalence was lower among white participants than other ethnicities [20,43,71].
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Multiple studies investigated associations between socioeconomic status and EBV seropositivity (Table 
1). Five reported no association [20,57,60,69,73], whereas eight showed that EBV seropositivity was low-
er in people with higher levels of education [10,19,20,43,57], higher socioeconomic status [10], social 
class or household income [43,71]. All the studies reporting an association between lower EBV preva-
lence and higher socioeconomic status examined young people (≤21 years), whereas those that found no 
association examined all ages.
There was mixed evidence regarding an association with household size or daycare attendance (Table 1). 
Crowding of the home was not associated with EBV [20,25,43,69]. These findings did not differ by study 
size, design, location or population. Four studies found that smoking or passive smoking was associated 
with higher EBV seroprevalence [10,39,66,79]; one study reported a dose-response effect [39]. However, 
a further six studies reported no association [19,56,60,61,64,75]. Again, there were no discernible design 
differences between studies (Table S1 in the Online Supplementary Document).
Four of six studies reported that seroprevalence was higher among those who were overweight/obese than 
people of a healthy weight for older children and adults [64,79-81], whilst two studies of very young chil-
dren and elderly women with physical difficulties reported no association [71,75]. Dietary factors were 
generally not associated with EBV seroprevalence (Table 1), nor were frequency of handwashing, house 
cleaning, or having pets in the house (Table 1).
Viral and immune factors associated with EBV seroprevalence
Thirteen studies reported data on the correlation between EBV and CMV seroprevalence (Table 2); ten 
reported a positive association [31,35,48,60,66,83-87]; however studies which reported a negative asso-
ciation or no association tended to lack power [62,88].
Table 2. Summary of viral and clinical factors associated with EBV serostatus in the literature
Risk factoR foR EBV sERostatus summaRy of REsults
CMV infection
Positive correlation between EBV and CMV serostatus: 10 studies [31,35,48,60,66,83-87]
Negative association: 1 study [62]
No association: 2 studies [88,89]
KSHV infection Positive correlation between EBV and KSHV: 1 study [41]
HTLV infection Positive correlation between EBV and HTLV serostatus: 1 study [77]
HSV-1 infection Positive correlation between EBV and HSV-1 serostatus: 1 study [83]
Toxoplasmosis infection No association: 1 study [89]
Rubella infection No association: 1 study [89]
Syphilis No association: 1 study [89]
Anti-IFN-gamma autoantibodies No association: 1 study [89]
HIV infection
HIV infection
Positive correlation between EBV and HIV status: 2 studies [8,17]
No association: 1 study [90]
CD4 count
No association: 2 studies [54,57]
Mother’s low CD4 percentage was associated with EBV seropositivity: 1 study [8]
Viral load
Mother’s higher viral load was associated with being EBV seropositive: 1 study [8]
Sensitised to IgE (allergy testing)
EBV-seronegative individuals had higher odds of ≥1 positive specific IgE test: 1 study [52]
No association: 1 study [24]
Maternal family history of atopy No association: 1 study [71]
Positive skin prick tests EBV-seronegative individuals had higher odds of ≥1 skin prick test: 1 study [52]
Breastfed
Breastfeeding
No association: 1 study [20]
Duration of being breastfed
No association with duration of being breastfed: 4 studies [8,25,66,71]
Respiratory or gastrointestinal 
tract infections in first year of life
No association: 1 study [71]
History of tonsillectomy More common among EBV seronegative individuals: 1 study [73]
CMV – cytomegalovirus, EBV – Epstein-Barr virus, HIV – human immunodeficiency virus, HSV – herpes simplex virus, HTLV – 
human T-cell lymphotrophic virus, IFN – interferon, IgE – immunoglobulin E, KSHV – Kaposi’s sarcoma-associated herpesvirus
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EBV seropositivity was also associated with infection with Kaposi’s sarcoma-associated herpesvirus (KSHV) 
[41], human T-cell lymphotropic virus (HTLV) [77], herpes simplex virus-1 (HSV-1) [83] and HIV [8,17]. 
CD4 count was not associated with EBV status in study participants with HIV (Table 2) [54,57], however, 
EBV seroprevalence was higher among infants whose mothers had HIV and were immunosuppressed [8].
There was some evidence of an association between EBV seroprevalence and positive allergy tests (Table 
2) [52], although other studies found no association with positive allergy tests or atopy [24,71]. Prior 
tonsillectomy was less common among those who were EBV seropositive [73]. There was no association 
with having been breastfed [20], duration of breastfeeding [8,25,66,71], or having other gastrointestinal 
or respiratory tract infections during the first year of life [71].
Genetic factors associated with EBV seronegativity
Three studies examined associations between immune system genes and EBV serostatus (Table 3). We 
refer here to associations with seronegativity, rather than seropositivity, as these are the genetic differenc-
es relevant to vaccination. Polymorphisms in the mannose-binding lectin gene [24], but not the defen-
sin beta 1 gene [64], were associated with EBV seronegativity in children. Polymorphisms regulating the 
function of HLA-Bw4 and HLA-C were associated with EBV seronegativity in a cohort of healthy peo-
ple aged >60 years [73]. Two other studies reported associations between gene polymorphisms and the 
EBV-specific antibody response in people that acquired the virus. None of these studies made adequate 
adjustments for confounding and their findings have not been replicated.
Table 3. Summary of human genetic factors associated with EBV serostatus in the literature
Risk factoR foR 
EBV sERostatus
summaRy of REsults
Immunological 
markers
HLA-C variant with the presence of TT at position -35 was more common in EBV seropositive individuals: 1 study [73]
Frequency of HLA-Bw4 epitopes was lower in EBV seronegative individuals: 1 study [73]
MBL-insufficient genotype (vs MBL-sufficient genotype) was associated with higher rates of EBV seronegativity: 1 study [23]
No association between haplotype of the β-defensin-1 gene (DEFB1) and EBV seroprevalence: 1 study [91]
EBV – Epstein-Barr virus, C – cytosine, HLA – human leukocyte antigen, IL – interleukin. MBL – mannose-binding lectin, T – thymine
DISCUSSION
Our systematic review of the literature is, to our knowledge, the first to summarise global risk factors for 
EBV infection whilst simultaneously assessing the quality of studies using a standardised tool. This formal 
assessment of the epidemiological evidence is critical to provide a comprehensive summary of the cur-
rent evidence base to inform the direction of future research and policy, and to identify gaps that exist in 
the literature either because of a total absence of research, or an abundance of poor-quality research. In-
creasing age and co-infection with CMV were strongly associated with higher EBV seroprevalence. Criti-
cally, infection with EBV occurred at a younger age in study populations in Asia than in Europe or North 
America. Additionally, socioeconomic status, household size, smoking, body mass index (BMI), co-in-
fections and genetic variants of immunological genes were associated with EBV serostatus, with varying 
degrees of certainty.
The age at which EBV infection occurs is an essential consideration when designing infection-prevent-
ing vaccination strategies. Variability in the age at infection between countries and settings will be a crit-
ical factor in deciding if, when, and how to roll out infection-preventing EBV vaccines in order to en-
sure cost-effectiveness, and whether or not a vaccine is cost-effective may differ between settings. Our 
literature review demonstrated that in Asian populations, where seroprevalence reached 80% by age 5, 
vaccinating infants would be essential to prevent infection. In contrast, in Europe and North America 
seroprevalence increases more gradually throughout childhood and adolescence, and the burden of IM 
is higher [3]. A vaccine like the original gp350-based based vaccine [92], which was unable to prevent 
infection but reduced IM incidence, could be deployed in these populations. Debilitating in its own 
right, IM is also associated with increased risk of developing EBV-positive Hodgkin’s lymphoma (HL) 
and multiple sclerosis (MS) [93,94], accordingly, a vaccine capable of reducing IM should decrease inci-
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dence of both conditions over time. A vaccine capable of preventing EBV infection from occurring could 
potentially have a much greater impact; reducing not only the incidence of HL but also of other malig-
nancies where EBV infection is necessary for pathogenesis, but IM has not been reported to increase the 
risk. In addition to cancers, a history of IM is also associated with an elevated risk of multiple sclerosis; 
an IM-preventing vaccine could therefore potentially reduce the risk of this common autoimmune dis-
ease. However, a much greater effect might be achieved by a fully protective EBV vaccine, since the rel-
ative risk of MS development in EBV seronegative individuals is substantially lower than that of those 
carrying the virus [95]. Multiple lines of evidence support a causal role for EBV in MS [95]. If EBV in-
fection is truly a pre-requisite for MS development then there is, in principle, no reason why a vaccine 
that prevents EBV infection would not prevent MS.
Importantly, incomplete vaccine coverage or imperfect efficacy could also increase the average age of EBV 
acquisition by reducing the pool of susceptible individuals, but not enough to prevent transmission; po-
tentially increasing the likelihood of EBV-infection associated sequelae such as IM. Vaccination against 
Varicella Zoster virus (the only herpesvirus currently preventable by vaccination) is not recommended 
unless high vaccine coverage can be achieved, because increasing the average age of infection results in 
greater severity of disease [96]. The impact of age at EBV infection on the incidence of EBV-associated 
cancers is relatively unknown. For an EBV vaccination program to prevent EBV-associated cancers, vac-
cination policies will also be dependent on the rates of EBV-associated cancers in different settings, and 
the age at which these cancers typically occur.
There is a considerable lack of data on EBV seroprevalence by age in Africa and South America, and 
many studies from Asia were not generalisable to the wider population, thus limiting their usefulness for 
vaccination planning. High-quality, setting-specific data on the age at which EBV infection is acquired 
are essential for understanding EBV epidemiology in different settings and informing effective local vac-
cination policies. Future work is also required to understand why some individuals remain EBV sero-
negative for life, and the implications of this, which has important implications before implementing 
any vaccination strategy.
Many sociodemographic risk factors have been associated with EBV infection, however the causality of 
these relationships is difficult to determine for two broad reasons. First, socioeconomic status (SES) is a 
complex and dynamic measure that reflects different levels of exposure to multiple environmental and 
lifestyle factors. Second, lower SES is linked to diverse multiple biological factors that include chronic 
stress, increased pro-inflammatory immune factors [97], lower overall immunity and potentially shorter 
telomere length [98], although the causal nature of these relationships are not understood. Many of these 
factors could conceivably alter susceptibility to EBV infection and the risk of EBV infection occurring at 
a younger age. Dedicated studies exploring a wide range of sociodemographic and lifestyle factors with-
in whole families are therefore needed to understand the causal factors leading to EBV infection in more 
detail, and these factors are likely to vary in different settings. Based on the current data it is, however, 
possible to make three general conclusions. First, the evidence showing SES was associated with EBV 
seroprevalence in studies of young people, but not in studies that included adults older than 21 years, 
suggests that SES is associated with the age at which EBV infection is acquired, but not with whether 
individuals remain uninfected for life. Thus, SES may have important effects on EBV-associated disease 
by mediating the age at which individuals are infected; it is known that EBV infection during adoles-
cence frequently causes IM. Second, risk factors relating to SES which may directly influence the risk 
of EBV transmission (such as household size and crowding) were not found to be associated with EBV 
serostatus in our review, although it is possible they may be associated with the age of infection, which 
we were not able to explore. Finally, the mixed evidence as to whether there is an association between 
smoking and EBV suggests that this could be due to the association with socioeconomic status, rather 
than smoking being an independent risk factor. Similarly, higher income and/or social class, or higher 
BMI are likely confounders for other causal factors, rather than having an independent effect. However, 
what these causal factors may be remains unclear.
A meta-analysis of the association between EBV seroprevalence and latitude (of the studies, not individ-
ual participants) reported that EBV seroprevalence increased with distance from the equator, and sug-
gested that as well as genetic, social and climactic factors, vitamin D may have a role in EBV-associated 
disease [99]. We did not identify any studies which looked at the association between vitamin D and 
EBV seroprevalence; this may merit further investigation.
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There was a consistently positive association between infection with EBV and CMV, however we were 
unable to determine the temporality of this relationship, as no studies found in the literature have ex-
amined whether one infection preceded the other. The association may result from shared genetic, im-
munological and/or sociodemographic risk factors, or one infection could increase susceptibility to the 
other. Longitudinal studies with serial testing are necessary to explore this association in more detail. 
We note that a variety of antibodies were used to measure seroprevalence across the different studies, 
providing an additional degree of heterogeneity. Although IgG is the most utilised as an indicator of an-
tibody-based immunity some studies also measured IgM (early-stage humoral immunity) and/or IgA 
(found in mucosal areas; IgA anti-VCA is more associated with nasopharyngeal carcinoma patients).
While multiple studies have studied links between genes involved in antiviral immunity and EBV-relat-
ed disease [2], we identified only three studies examining links between such genes and EBV serostatus 
within the time period of our inclusion criteria. This small number of studies may be a consequence of 
the low frequency of EBV seronegative individuals in the adult population meaning large cohorts are 
required to identify sufficient EBV seronegative donors to produce robust conclusions. All three genes 
identified as being associated with EBV serostatus (mannose-binding lectin, HLA-Bw4 and HLA-C) are 
involved in the innate immune system; and older, smaller studies have reported similar associations [100-
102]. Further studies are needed to determine the mechanisms by which these polymorphisms are asso-
ciated with a lack of EBV infection, and whether other genes are similarly associated with EBV serostatus.
The comprehensive search strategy for the systematic review was designed to be highly sensitive, and 
we included papers in any language to ensure our results were comprehensive. Heterogeneity in study 
design in the existing literature, and wide variation in the risk factors reported, meant that a formal me-
ta-analysis of our findings was not appropriate.
Confounding made it difficult to compare studies as there was substantial variation in the factors each 
paper adjusted for, and many studies only reported univariable results. However, this did not appear 
to cause systematic bias in the results. An important contribution of this study is that it will enable fu-
ture studies to be better informed regarding the confounders they need to control for in their analyses 
in order to ensure unbiased estimates of effect sizes for other risk factors. The majority of studies were 
cross-sectional, meaning that the temporality of associations could not be assessed. As EBV infection is 
often acquired a young age, it may have preceded the reported risk factors, particularly factors such as 
BMI, smoking and diet. It is unclear whether high BMI is a risk factor for EBV infection, whether EBV 
infection predisposes individuals to obesity, or whether BMI is a confounder for other factors causally 
associated with EBV. The majority of the studies we found were conducted in Europe, North America 
and Southeast Asia, therefore our findings may not be generalisable outside these settings.
CONCLUSIONS
In this systematic review we document the diverse factors that have been analysed globally for potential 
associations with EBV seroprevalence, provide a formal assessment of the quality of studies, and discuss 
the implications for future vaccine policy. EBV seroprevalence generally increases until around 24 years 
of age and remains constant thereafter; however infection is acquired earlier in Asia than in Europe and 
North America. Consequently, depending upon the efficacy and duration of protection of a vaccine, dif-
ferent vaccination strategies may be required in different settings. In Asia, vaccination of infants would be 
required to prevent EBV infection from occurring. In contrast, in Western countries a vaccine with lim-
ited duration of protection could prevent IM in older seronegative individuals, thereby reducing EBV-as-
sociated disease. There is a lack of high-quality data on the prevalence and age of EBV infection outside 
of Europe, North America and South-East Asia, which will be essential for informing effective vaccina-
tion policies in these settings.
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